Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Chimeric Therapeutics Reports Lapse of Performance Rights and Options

CHM: $0.003 +0.00% · MC: $442K

Chimeric Therapeutics reported that performance rights and options lapsed after their conditions were not met or could no longer be satisfied. The company also gave notice of its virtual annual general meeting, scheduled for November, where shareholders will consider a proposed additional share-issue capacity of up to 10% and the re-election of director Phillip Hains.

Source announcements: 2026-10-30 09:45 to 2026-10-30 15:16 Sydney time
Story updated 2026-10-30 15:23 Sydney time
SourcesNotice of Annual General Meeting/Proxy FormNotification of cessation of securities - CHM
Comments